Your browser doesn't support javascript.
loading
Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms.
Abdelhamid, Mohamed H; Zayed, Ahmed S; Ghoneima, Waleed E; Elmarakbi, Akrm A; El Sheemy, Mohamed S; Aref, Ahmed; Abdelbary, Ahmed; Nour, Hani H.
Affiliation
  • Abdelhamid MH; Department of Urology, Cairo University, Cairo, 11562, Egypt. haythamuro@yahoo.com.
  • Zayed AS; Department of Urology, Theodor Bilharz Research Institute, Giza, 12411, Egypt.
  • Ghoneima WE; Department of Urology, Cairo University, Cairo, 11562, Egypt.
  • Elmarakbi AA; Department of Urology, Beni-Suef University, Beni Suef, 62511, Egypt.
  • El Sheemy MS; Department of Urology, Cairo University, Cairo, 11562, Egypt.
  • Aref A; Department of Urology, Beni-Suef University, Beni Suef, 62511, Egypt.
  • Abdelbary A; Department of Urology, Beni-Suef University, Beni Suef, 62511, Egypt.
  • Nour HH; Department of Urology, Theodor Bilharz Research Institute, Giza, 12411, Egypt.
World J Urol ; 35(8): 1261-1268, 2017 Aug.
Article in En | MEDLINE | ID: mdl-28050642
ABSTRACT

PURPOSE:

We aimed to compare the safety and efficacy of solifenacin versus trospium chloride and compare each drug versus placebo regarding the relief of stent-related symptoms following uncomplicated ureteroscopic lithotripsy (URSL).

METHODS:

In a prospective, randomized, double-blind study, 210 eligible patients who underwent URSL with double-J stent insertion were recruited and randomly assigned to either the first group, receiving solifenacin (10 mg), second group, receiving trospium chloride (60 mg), or the third group, receiving placebo (one tablet). All patients were kept on study medication once daily during the entire 2-week postoperative period. All subjects were asked to complete a brief-form questionnaire to assess the lower urinary symptoms, stent-related body pain and hematuria, preoperatively and 2 weeks postoperatively.

RESULTS:

There were no statistically significant differences among the study groups in terms of mean age, gender, anthropometric measurements, stone and stent criteria. The overall symptom score, urgency, urge incontinence, flank pain, urethral pain and gross hematuria scores were significantly lower in solifenacin group compared to trospium chloride and placebo groups (p < 0.001). Concerning frequency and nocturia, there was no significant difference in mean scores across all groups. Drug-related side effects, particularly constipation, were higher in trospium group than in solifenacin one.

CONCLUSIONS:

Solifenacin treatment showed significant improvement in almost all domains of stent-related symptoms than trospium. In terms of safety and tolerance, both drugs were comparable. Future studies should be designed to address the impact of combined drugs and lower doses in the management of DJ stent-related symptoms.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Postoperative Complications / Benzilates / Kidney Calculi / Stents / Muscarinic Antagonists / Urinary Incontinence, Urge / Solifenacin Succinate / Nortropanes Type of study: Clinical_trials / Diagnostic_studies Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: World J Urol Year: 2017 Type: Article Affiliation country: Egypt

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Postoperative Complications / Benzilates / Kidney Calculi / Stents / Muscarinic Antagonists / Urinary Incontinence, Urge / Solifenacin Succinate / Nortropanes Type of study: Clinical_trials / Diagnostic_studies Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: World J Urol Year: 2017 Type: Article Affiliation country: Egypt